POMIDE 4MG

About

POMIDE 4MG contains Pomalidomide, an immunomodulatory drug (IMiD) with direct anti-tumor activity, immunomodulatory effects, and anti-angiogenic properties. It is primarily indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy. Pomalidomide works by directly inhibiting the proliferation of myeloma cells, inducing apoptosis, and enhancing T-cell and natural killer (NK) cell-mediated immunity. It also inhibits angiogenesis by blocking the production of pro-angiogenic factors.

Due to its teratogenic potential, POMIDE is available only through a restricted distribution program called the POMALYST REMS program. Patients must adhere to strict pregnancy prevention measures. Its unique mechanism of action makes it a valuable therapeutic option for patients with relapsed or refractory multiple myeloma, offering a distinct pathway to combat the disease when other treatments have failed.

Uses

• Relapsed/refractory multiple myeloma
• Kaposi's sarcoma (off-label)
• Myelodysplastic syndromes (off-label)
• Chronic lymphocytic leukemia (off-label)

Directions For Use

Take orally once daily on days 1-21 of a 28-day cycle. Swallow the capsule whole with water, without opening, breaking, or chewing.

Benefits

• Effective in relapsed/refractory multiple myeloma
• Improves progression-free survival
• Oral administration for patient convenience
• Distinct mechanism of action from other therapies
• Can be used after other IMiDs
• Part of effective combination regimens

Side Effects

• Neutropenia
• Thrombocytopenia
• Fatigue
• Anemia
• Constipation
• Diarrhea
• Nausea
• Dyspnea
• Peripheral neuropathy
• Deep vein thrombosis
• Pulmonary embolism
• Rash

Safety Measures

• Alcohol - Avoid or limit alcohol consumption due to potential for increased dizziness, fatigue, and other central nervous system side effects.
• Pregnancy - Contraindicated during pregnancy due to severe teratogenicity. Patients must enroll in a strict pregnancy prevention program (REMS) and use effective contraception.
• Breastfeeding - Not recommended during breastfeeding. It is unknown if Pomalidomide is excreted in human milk, but potential for serious adverse reactions in the infant exists.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustment may be needed for moderate to severe impairment, and liver function should be monitored.
• Kidney - Dose adjustment is required for patients with moderate to severe renal impairment, including those on dialysis. Monitor kidney function regularly.
• Lung - Monitor for signs and symptoms of thromboembolic events, including pulmonary embolism. Prophylactic anticoagulation may be considered based on individual risk factors.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.